Santarus Announces GlaxoSmithKline's Introduction Of ZEGERID Products In Puerto Rico, U.S. Virgin Islands - Quick Facts

(RTTNews) - Tuesday, pharma company Santarus, Inc. (SNTS | news | PowerRating | PR Charts ) announced that GlaxoSmithKline Plc (GSK | news | PowerRating | PR Charts ) has launched ZEGERID Capsules and ZEGERID Powder for Oral Suspension in Puerto Rico and the U.S. Virgin Islands.

The ZEGERID products, developed by Santarus, is indicated for the treatment of heartburn and other symptoms associated with gastroesophageal reflux disease, or GERD, maintenance of healing and short-term treatment of erosive esophagitis, and short-term treatment of active benign gastric ulcers and active duodenal ulcers.

According to the market research firm IMS Health Inc., retail sales of prescription PPI products in Puerto Rico and the U.S. Virgin Islands were approximately $124 million for the 12 months ended September 30, 2007 and grew at 24% compared with the prior 12-month period.

Santarus and GSK entered into a distribution agreement in November 2007 under which GSK will distribute, market and sell ZEGERID brand prescription products in Puerto Rico and the U.S. Virgin Islands. Meanwhile, Santarus licensed rights to GSK to develop, manufacture and commercialize immediate-release omeprazole products in up to 114 countries in GSK's International Region, including in Africa, Asia, the Middle-East, and Central and South America.

For comments and feedback: contact editorial@rttnews.com Copyright(c) 2008 RealTimeTraders.com, Inc. All Rights Reserved

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index